N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.

[1]  C. Sawyers,et al.  A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon , 2016, PloS one.

[2]  L. Zender,et al.  A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer , 2016, Nature Medicine.

[3]  M. Rubin,et al.  Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT). , 2016 .

[4]  Joshua M. Stuart,et al.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. , 2016, Cancer cell.

[5]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[6]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[7]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[8]  May D. Wang,et al.  Comparison of RNA-seq and microarray-based models for clinical endpoint prediction , 2015, Genome Biology.

[9]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[10]  T. Ratajczak,et al.  Steroid Receptor-Associated Immunophilins: A Gateway to Steroid Signalling. , 2015, The Clinical biochemist. Reviews.

[11]  Jiao Zhang,et al.  Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[13]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[14]  Erin F. Simonds,et al.  Drugging MYCN through an allosteric transition in Aurora kinase A. , 2014, Cancer cell.

[15]  F. Westermann,et al.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.

[16]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[17]  M. Fischer,et al.  Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. , 2013, Cancer cell.

[18]  D. Zheng,et al.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.

[19]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[20]  C. Liang,et al.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. , 2012, Endocrine-related cancer.

[21]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[22]  P. Humphrey.  Histological variants of prostatic carcinoma and their significance , 2012, Histopathology.

[23]  A. D. De Marzo,et al.  Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms , 2011, Oncotarget.

[24]  R. Montironi,et al.  ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin , 2011, Modern Pathology.

[25]  K. Sheahan,et al.  Primary intrahepatic small-cell carcinoma arising from combined hepatocellular and cholangiocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. M. Simpson,et al.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. , 2011, The American journal of pathology.

[27]  L. Tran,et al.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.

[28]  C. Bieberich,et al.  ERG gene rearrangements are common in prostatic small cell carcinomas , 2011, Modern Pathology.

[29]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[30]  Markus Reischl,et al.  ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor , 2010, Modern Pathology.

[31]  R. Beijersbergen,et al.  Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. , 2009, Cancer cell.

[32]  R. Eils,et al.  Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.

[33]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[34]  W. Weiss,et al.  Childhood tumors of the nervous system as disorders of normal development , 2006, Current opinion in pediatrics.

[35]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[36]  D. Rowitch,et al.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. , 2006, Cancer research.

[37]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[38]  S. Batra,et al.  Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. , 2006, Endocrine-related cancer.

[39]  William C Hahn,et al.  The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. , 2005, Developmental cell.

[40]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[41]  A. Parwani,et al.  Prostate Carcinoma With Squamous Differentiation: An Analysis of 33 Cases , 2004, The American journal of surgical pathology.

[42]  R. Aebersold,et al.  Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. , 2003, Molecular endocrinology.

[43]  R. Minchin,et al.  Immunophilin chaperones in steroid receptor signalling. , 2003, Current topics in medicinal chemistry.

[44]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Tachibana,et al.  Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. , 2001, Oncology reports.

[46]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[47]  C. Olsson,et al.  Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. , 1997, Urologic oncology.

[48]  L. Mott,et al.  Squamous cell carcinoma of the prostate: report of 2 cases and review of the literature. , 1979, The Journal of urology.

[49]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[50]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.